phospholipid
content
er
membran
differ
plasma
membran
pm
phospholipas
pla
superfamili
consist
larg
number
member
specif
catalys
hydrolysi
phospholipid
particular
posit
show
cmii
isoform
secret
pla
obtain
naja
mossambica
mossambica
snake
venom
cmiispla
possess
potent
virucid
neutralis
activ
hcv
denv
jev
inhibitori
concentr
ic
ng
ml
respect
contrast
ic
valu
cmiispla
virus
bud
pm
sindbi
viru
influenza
viru
sendai
viru
transgolgi
network
tgn
herp
simplex
viru
ngml
moreov
cytotox
cc
haemolyt
hc
concentr
cmiispla
ngml
impli
cmiispla
significantli
damag
pm
result
suggest
cmiispla
deriv
good
candid
develop
broadspectrum
antivir
drug
target
viral
envelop
lipid
bilay
deriv
er
membran
cellular
membran
compart
categoris
two
group
first
group
consist
endoplasm
reticulum
er
nuclear
envelop
lipid
droplet
cisgolgi
ernecisgolgi
lipid
territori
second
group
consist
transgolgi
plasma
membran
pm
endosom
transgolgipme
membran
territori
ernecisgolgi
membran
lipid
pack
defect
wherea
transgolgipme
membran
show
tight
pack
phospholipid
addit
phospholipid
content
ernecisgolgi
membran
differ
transgolgipme
membran
envelop
virus
acquir
envelop
lipid
bilay
host
cellular
membran
consequ
phospholipid
content
virus
bud
ernecisgolgi
membran
differ
virus
bud
transgolgipme
membran
moreov
physicochem
characterist
thick
sturdi
differ
ernecisgolgi
transgolgipme
membran
moreov
sensit
hydrolysi
secret
phospholipas
spla
enzym
report
differ
depend
lipid
composit
overal
structur
hepat
c
viru
hcv
dengu
viru
denv
japanes
enceph
viru
jev
yellow
fever
viru
yfv
belong
famili
flavivirida
bud
er
membran
acquir
envelop
convers
influenza
viru
fluav
bud
pm
phospholipid
content
differ
denv
spla
obtain
venom
snake
report
possess
potent
virucid
neutralis
activ
denv
yfv
disrupt
viral
envelop
lipid
bilay
human
spla
also
show
virucid
activ
human
immunodefici
viru
hiv
known
bud
pm
moreov
spla
obtain
venom
bee
anoth
snake
naja
mossambica
mossambica
report
inhibit
entri
hiv
host
cell
without
disrupt
viral
envelop
examin
plant
anim
substanc
neutralis
activ
hcv
becam
interest
test
number
spla
differ
sourc
regard
specif
differ
virus
member
larg
spla
famili
show
highli
divers
sequenc
variat
function
characterist
divid
group
subgroup
spla
obtain
n
mossambica
venom
belong
subgroup
ia
subdivid
least
isoform
includ
cmi
ii
iii
subgroup
ib
includ
pancreat
spla
human
bovin
porcin
group
iii
xiv
includ
honeybe
venom
spla
bacteri
spla
respect
present
studi
examin
possibl
virucid
activ
spla
panel
virus
found
spla
cmii
isoform
n
mossambica
cmiispla
show
potent
virucid
activ
hcv
denv
jev
cmiispla
possess
potent
virucid
activ
hcv
denv
jev
bud
er
membran
virus
bud
pm
first
test
possibl
direct
virucid
activ
cmiispla
infecti
particl
panel
virus
viru
incub
variou
concentr
cmiispla
medium
control
h
inocul
onto
cell
h
viru
adsorpt
residu
viru
remov
wash
cell
medium
cell
cultur
h
cell
subject
fluoresc
antibodi
fa
stain
respect
antivir
antibodi
determin
number
virusinfect
cell
repres
inoculum
viral
titr
cellinfect
unit
ciu
ml
experi
plaqu
assay
tissu
cultur
infecti
dose
tcid
assay
perform
determin
viral
titr
inocula
plaqueform
unit
pfu
ml
tcid
ml
respect
inhibitori
concentr
ic
calcul
base
percent
reduct
initi
viral
titr
result
demonstr
cmiispla
effici
neutralis
infect
hcv
denv
jev
inhibitori
concentr
ic
ngml
nm
ngml
nm
ngml
nm
respect
tabl
dosedepend
inhibit
virus
cmiispla
shown
supplementari
fig
hcv
denv
jev
belong
famili
flavivirida
known
bud
er
membran
convers
cmiispla
even
dose
ngml
exert
signific
virucid
activ
sindbi
viru
sinv
togavirida
influenza
viru
fluav
orthomyxovirida
sendai
viru
sev
paramyxovirida
known
bud
pm
herp
simplex
viru
type
herpesvirida
bud
transgolgi
network
tgn
vesicular
stomat
new
jersey
viru
vsnjv
rhabdovirida
also
bud
pm
show
weak
sensit
cmiispla
ic
valu
ngml
weak
cmiispla
sensit
vsnjv
compar
insensit
sinv
fluav
could
attribut
bulletshap
configur
vsnjv
might
harbour
lipid
pack
defect
bottom
edg
bulletshap
particl
cmiispla
inhibit
hiv
infect
ic
ngml
result
consist
previou
observ
spla
obtain
bee
snake
venom
inhibit
hiv
entri
host
cell
without
disrupt
hiv
particl
also
test
middl
east
respiratori
syndrom
coronaviru
merscov
member
famili
coronavirida
known
bud
ergolgi
intermedi
compart
ergic
ergic
constitut
part
ernecisgolgi
territori
therefor
consid
similar
characterist
er
rather
unexpectedli
found
cmiispla
exert
margin
virucid
activ
merscov
ic
ngml
assum
except
larg
petalshap
spike
project
approxim
nm
virion
envelop
characterist
featur
member
coronavirida
interfer
access
cmiispla
envelop
lipid
bilay
altern
dosedepend
inhibit
pattern
see
panel
supplementari
fig
may
impli
possibl
two
group
merscov
particl
one
sensit
ngml
cmiispla
anoth
resist
ng
ml
cmiispla
latter
group
may
repres
viral
particl
bud
pm
report
previous
studi
need
elucid
issu
expect
cmiispla
neutral
infect
encephalomyocard
viru
emcv
coxsackieviru
belong
famili
picornavirida
possess
envelop
even
ngml
dose
timeofaddit
experi
perform
examin
whether
cmiispla
inhibit
viral
replic
viru
enter
host
cell
result
show
postinocul
postentri
treatment
hcvand
denvinfect
cell
cmiispla
ngml
h
reduc
number
infect
cell
see
supplementari
tabl
examin
viral
protein
synthesi
rna
replic
infect
cell
experiment
condit
result
demonstr
wherea
pretreat
viru
cmiispla
dose
low
ngml
almost
complet
inhibit
hcv
denv
infect
postentri
treatment
virusinfect
cell
cmiispla
even
ngml
dose
inhibit
viral
protein
synthesi
fig
rna
replic
fig
notabl
pretreat
cell
cmiispla
ngml
dose
prior
viral
inocul
result
substanti
inhibit
viral
replic
result
consist
result
shown
supplementari
tabl
determin
whether
cmiispla
bound
taken
cell
releas
medium
viral
inocul
neutralis
infect
inoculum
whether
cmiispla
treatment
induc
downregul
viral
receptor
andor
upregul
antivir
statu
cell
requir
investig
case
result
confirm
potent
virucid
activ
cmiispla
hcv
denv
cmiispla
mediat
vitro
cytotox
haemolyt
activ
also
test
cytotox
haemolyt
activ
cmiispla
uninfect
cell
incub
variou
concentr
cmiispla
h
cell
viabil
determin
use
assay
lactat
dehydrogenas
ldh
releas
test
cytotox
concentr
cc
calcul
haemolysi
assay
perform
incub
human
red
blood
cell
rbc
cmiispla
h
haemolyt
concentr
hc
calcul
cmiispla
even
ngml
dose
mediat
margin
cytotox
haemolyt
activ
tabl
select
indic
cc
ic
cmiispla
hcv
denv
respect
spla
bee
venom
group
iii
possess
moder
virucid
activ
hcv
denv
jev
wherea
spla
bovin
porcin
pancrea
subgroup
ib
bacteria
group
xiv
exert
signific
virucid
activ
next
test
possibl
virucid
activ
spla
group
subgroup
result
show
spla
obtain
bovin
porcin
pancrea
subgroup
ib
streptomyc
violaceorub
group
xiv
neutralis
hcv
denv
jev
even
ngml
dose
tabl
howev
spla
obtain
venom
honeybe
api
mellifera
group
iii
show
moder
degre
virucid
activ
hcv
denv
jev
ic
valu
ngml
respect
mediat
detect
cytotox
haemolyt
activ
even
ngml
dose
tabl
spla
inhibitor
manoalid
counteract
antivir
activ
cmiispla
hcv
denv
manoalid
known
irrevers
inhibit
enzymat
activ
spla
test
possibl
inhibitori
effect
manoalid
virucid
activ
cmiispla
cmiispla
incub
presenc
absenc
manoalid
buffer
contain
mm
hepe
ph
mm
cacl
h
manoalidetr
cmiispla
untreat
control
test
virucid
activ
hcv
denv
result
clearli
show
virucid
activ
cmiispla
hcv
denv
markedli
inhibit
manoalid
tabl
find
suggest
virucid
activ
cmiispla
hcv
denv
close
associ
enzymat
activ
pla
superfamili
current
classifi
six
type
name
spla
ca
depend
cytosol
cpla
ca
independ
cytosol
ipla
plateletactiv
factor
acetyl
hydrolas
pafah
lysosom
lpla
adiposespecif
adpla
onethird
member
pla
superfamili
belong
spla
divid
group
eg
ii
iii
xiv
subgroup
eg
ia
ib
iia
addit
highli
divers
sequenc
variat
spla
show
function
variat
involv
wide
rang
biolog
function
diseas
occurr
lipid
metabol
signal
moreov
spla
enzym
catalys
hydrolysi
posit
glycerol
backbon
phospholipid
present
studi
demonstr
cmiispla
belong
subgroup
ia
possess
potent
virucid
neutralis
activ
hcv
denv
jev
particl
bud
er
neutralis
infect
sinv
fluav
sev
bud
pm
tgn
tabl
potent
virucid
activ
hcv
denv
markedli
inhibit
specif
spla
inhibitor
tabl
result
suggest
cmiispla
select
disrupt
viral
envelop
lipid
bilay
deriv
er
phospholipid
hydrolysi
although
could
obtain
direct
evid
neg
stain
electron
microscop
analysi
viral
particl
phospholipid
content
ernecisgolgi
membran
differ
transgolgipme
membran
basic
account
differ
phospholipid
content
viral
envelop
virus
bud
ernecisgolgi
membran
bud
transgolgipme
membran
exampl
virus
bud
er
hcv
bovin
viral
diarrhea
viru
bvdv
report
contain
phosphatidylcholin
less
phosphatidylserin
virus
differ
mainli
reflect
intrins
chemic
differ
er
pm
addit
biophys
thick
sturdi
differ
er
pm
former
thin
less
sturdi
lipid
pack
defect
lipid
bilay
latter
thick
sturdier
tight
lipid
packag
moreov
envelop
protein
virus
belong
famili
flavivirida
lie
flat
across
surfac
lipid
bilay
virion
allow
spla
access
lipid
bilay
easili
lipid
bilay
envelop
virus
protrud
envelop
protein
physicochem
structur
differ
lipid
bilay
whole
envelop
would
account
specif
virucid
activ
cmiispla
differ
virus
sens
cmiispla
possibl
spla
use
examin
bud
site
infecti
particl
variou
virus
detail
also
need
take
consider
phospholipid
composit
viral
envelop
vari
even
among
differ
viral
speci
given
viral
famili
eg
hcv
denv
bvdv
west
nile
viru
wnv
famili
flavivirida
sinc
substrat
specif
spla
differ
depend
intrins
properti
specif
virucid
activ
spla
given
viru
like
determin
particular
composit
phospholipid
distribut
viral
envelop
moreov
lipid
composit
hcv
wnv
bvdv
bud
er
membran
report
differ
typic
er
membran
thu
virus
probabl
modifi
intracellular
microenviron
includ
physicochem
condit
host
cell
membran
facilit
progeni
viru
product
cmiispla
shown
mediat
neurotox
vivo
although
lesser
extent
cmiii
isoform
n
mossambica
spla
cmiii
isoform
neurotox
spla
possess
pmdisrupt
activ
high
bind
affin
ntype
neuronaltyp
receptor
latter
close
associ
neurotox
therefor
cmiispla
conceiv
taken
neural
cell
bind
receptor
eg
ntype
receptor
disrupt
certain
intracellular
membran
compart
insid
neuron
cell
mediat
neurotox
take
advantag
intrins
differ
physicochem
properti
membran
lipid
bilay
virus
host
cell
well
specif
interact
spla
receptor
broadspectrum
antivir
spla
develop
target
viral
envelop
lipid
bilay
deriv
er
without
target
lipid
bilay
host
cell
membran
cmiispla
mutant
weaker
bind
affin
ntype
receptor
retain
potent
virucid
activ
would
good
candid
develop
novel
antivir
drug
chemic
cmiispla
spla
obtain
mellifera
honeybe
venom
bovin
pancrea
violaceorub
purchas
sigmaaldrich
spla
porcin
pancrea
kind
gift
sanyo
fine
osaka
japan
manoalid
purchas
abcam
sev
fushimi
strain
vsnjv
strain
emcv
strain
nanci
strain
strain
merscov
strain
describ
previous
hcv
denv
jev
sinv
vsnjv
emcv
prepar
cell
fluav
merscov
prepar
mdck
vero
cell
respect
sev
prepar
embryon
egg
infect
virus
except
merscov
determin
cell
plaqu
assay
perform
sinv
vsnjv
emcv
cultiv
virusinocul
cell
day
overlay
medium
contain
methylcellulos
describ
previous
viral
titr
express
pfuml
remain
virus
except
infect
determin
fa
method
use
specif
antibodi
respect
virus
viral
titr
express
ciuml
describ
previous
briefli
viral
sampl
serial
dilut
complet
medium
inocul
onto
cell
seed
glass
coverslip
plate
viru
adsorpt
h
cell
wash
medium
remov
residu
viru
cultur
h
virusinfect
cell
wash
phosphatebuff
salin
pb
fix
paraformaldehyd
min
permeabilis
triton
pb
min
room
temperatur
wash
three
time
pb
cell
incub
virusspecif
primari
antibodi
h
follow
incub
fitcconjug
respect
secondari
antibodi
h
cell
observ
fluoresc
microscop
infect
determin
tzmbl
assay
use
receptorexpress
hela
cell
viral
titr
express
base
activ
report
previous
merscov
infect
determin
fa
method
use
specif
antibodi
vero
cell
h
infect
also
tcid
assay
vero
cell
cultiv
virusinocul
cell
day
follow
fix
phosphatebuff
formalin
stain
crystal
violet
cell
cultiv
dulbecco
modifi
eagl
medium
supplement
cell
growth
mainten
cultur
foetal
bovin
serum
nonessenti
amino
acid
penicillin
iuml
streptomycin
co
incub
antibodi
uvinactiv
antihcv
human
serum
rabbit
antisera
fluav
sev
merscov
describ
previous
mous
monoclon
antibodi
hcv
millipor
rabbit
polyclon
antibodi
denv
prm
genetex
jev
genetex
dehydrogenas
gapdh
millipor
rabbit
antisera
denka
seiken
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
goat
antirabbit
igg
life
technolog
purchas
scientif
report
virucid
neutralis
activ
test
cell
seed
well
plate
plaqu
assay
plate
tcid
test
cover
slip
well
plate
fa
test
fix
amount
test
viru
mix
serial
dilut
spla
incub
h
mixtur
inocul
onto
cell
incub
anoth
h
allow
viru
adsorpt
cell
wash
medium
remov
residu
viru
cultur
day
plaqu
assay
tcid
test
h
fa
test
day
tzmbl
assay
fresh
medium
without
spla
viral
solut
treat
spla
serv
control
percent
inhibit
viral
infect
spla
compar
untreat
control
calcul
ic
determin
timeofaddit
test
cmiispla
ad
viru
andor
cell
differ
time
point
rel
viru
inocul
describ
pretreat
cell
cmiispla
viru
inocul
examin
possibl
induct
antivir
statu
cell
cell
treat
cmiispla
h
wash
medium
remov
cmiispla
cell
inocul
viru
absenc
cmiispla
anoth
h
residu
viru
remov
cell
cultur
h
absenc
cmiispla
ii
pretreat
viru
cmiispla
follow
inocul
viruscmiispla
mixtur
onto
cell
examin
direct
virucid
activ
viru
incub
cmiispla
h
mixtur
inocul
onto
cell
h
viral
adsorpt
cell
wash
medium
remov
viru
cmiispla
cultur
h
absenc
cmiispla
iii
postinocul
postentri
treatment
virusinfect
cell
cmiispla
examin
postentri
antivir
activ
infect
cell
cell
inocul
viru
absenc
cmiispla
h
viral
adsorpt
cell
wash
medium
remov
viru
cultur
h
presenc
cmiispla
viral
titr
inoculum
degre
viral
protein
synthesi
viral
rna
replic
determin
infect
assay
immunoblot
quantit
rtpcr
qrtpcr
analys
respect
immunoblot
analysi
immunoblot
perform
report
previous
slight
modif
briefli
cell
lyse
laemmli
sampl
buffer
biorad
cell
lysat
separ
sdspolyacrylamid
gel
electrophoresi
transfer
polyvinyliden
difluorid
membran
membran
probe
primari
antibodi
describ
follow
incub
appropri
hrpconjug
secondari
antibodi
band
visualis
use
immobilon
western
chemiluminesc
hrp
substrat
millipor
imagequ
la
ge
healthcar
qrtpcr
describ
previous
amount
denv
rna
determin
taqman
qrtpcr
accord
protocol
report
ito
et
al
cytotox
assay
cytotox
test
perform
use
reagent
roch
report
previous
briefli
cell
plate
well
plate
treat
serial
dilut
spla
h
untreat
cell
serv
control
treatment
reagent
ad
well
cell
cultur
h
reagent
convert
formazan
mitochondri
dehydrogenas
amount
formazan
determin
measur
absorb
well
use
micropl
reader
nm
percent
cell
viabil
compar
untreat
control
calcul
dilut
spla
cc
determin
ldh
releas
assay
perform
use
commerci
avail
kit
takara
bio
accord
manufactur
instruct
haemolyt
activ
assay
haemolyt
activ
test
use
human
rbc
report
previous
modif
briefli
fresh
human
rbc
wash
three
time
buffer
nacl
mm
hepe
ph
resuspend
buffer
rbc
suspens
rbcsml
ad
anoth
buffer
nacl
mm
hepe
ph
mm
cacl
contain
variou
dilut
spla
final
volum
mixtur
incub
h
centrifug
haemolysi
determin
measur
absorb
supernat
nm
control
zero
haemolysi
haemolysi
consist
rbc
suspend
buffer
triton
buffer
solut
distil
water
respect
percentag
haemolysi
calcul
dilut
spla
hc
determin
